USAMMDAUnited States Army Medical Materiel Development Activity
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
This NDA submission is a culmination of over 30 years of research and development with the US Army Medical Research and Materiel Command, from the discovery of Tafenoquine at Walter Reed Army Institute of Research (WRAIR) through the current collaboration between the company and USAMMDA, added the company.
Therefore, USAMMDA has made the development of a commercially available source of freeze-dried plasma a top priority.
In April 2014, Vascular Solutions entered into a Cooperative Research and Development Program with USAMMDA. Under the CRADA, USAMMDA provides funding for the regulatory and clinical work, and Vascular Solutions owns all intellectual property and commercial rights to the product.
USAMMDA is responsible for sponsoring, managing, and funding all preclinical and clinical studies required to support a Biologic License Application for commercialization.
Due to the difficulty of using current forms of plasma in remote locations such as in theater medical facilities and battlefield situations, USAMMDA has sought the development of a stable, durably-packaged freeze-dried plasma product that can be easily stored, transported, and administered in remote conditions.
The company has signed the agreement with the US Army Medical Materiel Development Activity (USAMMDA)
USAMMDA is the Department of Defense's (DoD) advanced development activity for products designed to protect and preserve the lives of Warfighters.